The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Open accessAbstract
Mosunetuzumab, a CD20×CD3 T-cell engaging bispecific antibody, redirects T cells to eliminate malignant B cells. We present updated efficacy and safety data of a pivotal phase 1/2 study after a median follow-up of 37.4 months in 90 patients with relapsed/refractory (R/R) follicular lymphoma (FL) and ≥2 prior lines of therapy treated with fixed-duration mosunetuzumab. Investigator-assessed complete response (CR) rate and objective response rate were 60.0% (95% confidence interval [CI], 49.1-70.2) and 77.8% (95% CI, 67.8-85.9), respectively. Among 70 responders, median duration of response was 35.9 months (95% CI, 20.7 to not estimable [NE]). Among 54 patients who achieved CR, 49 remained in CR at the end of treatment; median duration of CR was not reached (NR; 95% CI, 33.0 to NE); Kaplan-Meier-estimated 30-month remission rate was 72.4% (95% CI, 59.2-85.6). Estimated 36-month overall survival (OS) rate was 82.4% (95% CI, 73.8-91.0); median OS was NR (95% CI, NE to NE). Median progression-free survival was 24.0 months (95% CI, 12.0 to NE). Median time to CD19+ B-cell recovery was 18.4 months (95% CI, 12.8-25.0) after 8 cycles of mosunetuzumab treatment. No new cytokine release syndrome events or fatal, serious, or grade ≥3 adverse events were reported. With extended follow-up, mosunetuzumab demonstrated high response rates, durable remissions, and manageable safety with no long-term concerns. This supports outpatient mosunetuzumab administration as an off-the-shelf, fixed-duration, safe, and effective treatment for patients with R/R FL, including those with high-risk disease. This trial was registered at www.clinicaltrials.gov as #NCT02500407.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which might represent a more treatment-resistant population than inMIND, where 7% of participants”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“were higher for participants treated with epcoritamab plus R² due to overlapping toxicities in line with previous reports of T-cell engaging immunotherapies.”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [26]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“84% overall response rate”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [26]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the recently reported phase 3 inMIND trial, tafasitamab plus R² led to a 57% reduction in the risk of disease progression or death”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [26]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“minimal overlapping toxicities to R²”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [26]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09730 · Cited by 949
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 666
Pastore, A., Jurinovic, V., Kridel, R., Hoster, E., Staiger, A. M., Szczepanowski, M., Pott, C., Kopp, N., Murakami, M., Horn, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00169-2 · Cited by 618
Self-citationMorschhauser, F., Tilly, H., Chaidos, A., McKay, P., Phillips, T., Assouline, S., Batlevi, C. L., Campbell, P., Ribrag, V., Damaj, G. L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30441-1 · Cited by 604
Self-citationTisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01622-0 · Cited by 555
Self-citation
Research works printed but not linked: 2
- Assouline, 2024, Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥3 years of follow-up: subgroup analysis of a pivotal phase II study, Hemasphere, 8, 288
- van de Weil, 2021, Manufacturing commercial axicabtagene ciloleucel for European patients: a 2- year retrospective analysis [abstract], Hemasphere, 5, 691
Cited by
Bispecific antibodies: unleashing a new era in oncology treatment
Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 57
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02360-8 · Cited by 41
Reprogramming cancer immunity with next-generation combination therapies
Kyriakidis, N. C., Echeverría, C. E., Bautista, J., Rivera-Orellana, S., Ramos-Medina, M. J., Salazar-Santoliva, C., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Guerrero, S. X., & López‐Cortés, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1652047 · Cited by 31
Amoozgar, B., Bangolo, A., Habibi, M., Cho, C., & Goy, A. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115319 · Cited by 24
van Besien, H. J., Easwar, N., Demetres, M. R., Pasciolla, M. S., Shore, T. B., Leonard, J. P., Barker, J. N., Martin, P., & Yamshon, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016291 · Cited by 26
Metadata
- Authors
- Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., Fay, K., Ku, M., Nastoupil, L. J., Wei, M. C., Yin, S., To, I., Kaufman, D., Kwan, A., Penuel, E., Bolen, C. R., & Budde, L. E.
- Affiliations
- BC Cancer Agency (CA)
- Washington University in St. Louis (US)
- Rutgers Cancer Institute (US)
- Abramson Cancer Center (US)
- Jewish General Hospital (CA)
- Royal Adelaide Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- Fred Hutch Cancer Center (US)
- The University of Western Australia (AU)
- Heidelberg University (DE)
- Royal North Shore Hospital (AU)
- The University of Melbourne (AU)
- The University of Texas MD Anderson Cancer Center (US)
- Genentech (US)
- City Of Hope National Medical Center (US)
- Corresponding author
- Budde, Lihua E.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2025-02-13
- Volume
- 145
- Issue
- 7
- Pages
- 708-719
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4403709325
- Cited by
- 94
- References
- 39
- Citations by year
- 2026: 48 · 2025: 46
- FWCI
- 28.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Teva Pharmaceutical Industries
- Celgene
- F. Hoffmann-La Roche
- TG Therapeutics
- MEI Pharma
- BeiGene
- Incyte
- Royal Adelaide Hospital
- MorphoSys
- Genentech
- Kite Pharma
- Pharmacyclics
- Janssen Research and Development
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Keywords
- mosunetuzumab, relapsed/refractory follicular lymphoma, T-cell engagers, fixed-duration treatment, complete response, duration of response, overall survival, progression-free survival, B cell recovery, cytokine release syndrome, long-term safety, high-risk follicular lymphoma
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Lymphoma, Follicular, Male, Middle Aged, Neoplasm Recurrence, Local, Recurrence, Antibodies, Bispecific
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. https://app.cochat.ai/papers/10.1182/blood.2024025454
- The paper
- Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., Fay, K., Ku, M., Nastoupil, L. J., Wei, M. C., Yin, S., To, I., Kaufman, D., Kwan, A., Penuel, E., . . . Budde, L. E. (2025). Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood. https://doi.org/10.1182/blood.2024025454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.